Epkinly (epcoritamab-bysp) / Genmab, AbbVie - LARVOL DELTA

Epcoritamab Monotherapy in Patients with First-Line Richter's Transformation: 2-Year Follow-Up Results From the Phase 1b/2 EPCORE CLL-1 Clinical Trial (IWCLL 2025) - P1/2 | "Epcoritamab monotherapy induced high response rates with prolonged survival in patients with 1L RT, of whom 95% had prior CLL-directed therapy, a population with historically poor outcomes. Epcoritamab demonstrated a manageable safety profile that was consistent with that described for other disease states, with predominantly low-grade CRS that resolved, and no new safety concerns. These results underscore the clinical potential of epcoritamab in RT and support its ongoing evaluation in combination with other treatment modalities for non-Hodgkin lymphoma, including RT."

Clinical • Monotherapy • P1/2 data • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Richter's Syndrome • Small Lymphocytic Lymphoma • TP53

Hematopoietic Progenitor Kinase-1 (HPK-1) Inhibition Improves the In Vitro Efficacy ofBispecific Antibodies in CLL (IWCLL 2025) - "Aims: This study aimed to explore the effectiveness of HPK-1 inhibition combined with CD20XCD3 bispecific antibodies as a treatment strategy for CLL. Peripheral blood mononuclear cells (PBMCs) from CLL patients were treated with selective HPK-1 inhibitors, such as HY-138568 or BGB15025, and subsequently activated with anti-CD3/CD28 antibodies. PBMCs from CLL patients treated with HPK-1 inhibitors and activated with anti-CD3/CD28 beads showed a significant increase in CD69 and CD25 surface expression on CD8+ T cells, with no significant change in CD4+ T cells. Additionally, HPK-1 inhibitor pretreatment led to a notable increase in IFN-γ and granzyme B release in response to CD3/CD28 activation. The incubation of CLL patient PBMCs with CD20xCD3 bispecific antibodies, including mosunetuzumab, epcoritamab, and glofitamab, resulted in increased IFNγ secretion, particularly with glofitamab."

Preclinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • CD4 • CD69 • CD8 • GZMB • IFNG • IL2RA

Novel Immunotherapy Combinations in Indolent Lymphoma (SOHO 2025) - P1/2, P2, P3 | "The MITHIC-FL1 Table Overview of BsAb combination studies in patients with FL Trial /NCT Phase Treatment setting Number of patients Description Outcomes CRS Median follow-up EPCORE NHL-2, Arm 2 NCT04663347 Phase 1b/2 Relapse/ refractory 111 subcutaneous epcoritamab with R² ORR: 96% CR: 87% Grade 1 – 2: 46% Grade 3: 2% 25.3 months EPCORE FL1 NCT05409066 Phase 3 Relapse/ refractory 500 subcutaneous epcoritamab with R² vs R² NA NA Jan 2030 27 Grade 1 – 2: 25% (mostly grade 1) NA NCT04246086 Phase 1b Relapse/ refractory mosunetuzumab plus lenalidomide ORR: 92%; CR- 77% CELESTIMO NCT04712097 Phase 3 Relapse/ refractory 400 NA NA mosunetuzumab plus lenalidomide vs rituximab plus lenalidomide NA NCT06453044 Phase 2 NA March 2028 Relapse/ refractory 41 mosunetuzumab and polatuzumab vedotin NA NCT04077723 Phase 1 subgroup englumafusp alfa combined with glofitamab ORR: 91% CR: 80% Relapse/ refractory 134 pts total , 24 in the iNHL Grade 1 – 2: 63%..."

Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Oncology

Bispecific Antibodies and Antibody-Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma. (PubMed, Cancers (Basel)) - "Bispecific antibodies, including epcoritamab and glofitamab, third-line therapies for diffuse large B-cell lymphoma, are recombinant immunoglobulins engineered to recognize two distinct antigens or epitopes simultaneously...In the context of new therapies, antibody-drug conjugates, such as loncastuximab tesirine, are therapies composed of monoclonal antibodies linked to cytotoxic agents, in which the antibody selectively binds to tumor-associated antigens, delivering the cytotoxic payload directly to cancer cells while minimizing off-target effects...Ongoing clinical trials are investigating other molecules like odronextamab and the use of bispecific antibodies in combination regimens and earlier lines of therapy. The aim of this review is to explore actual therapies in relapsed/refractory diffuse large B-cell lymphoma, focusing on bispecific antibodies and antibody-drug conjugates."

Journal • Review • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

From R-CHOP to Revolution: How CAR T-Cells, ADCs, and Bispecific Antibodies Are Transforming DLBCL Treatment. (PubMed, Crit Rev Oncol Hematol) - "Novel therapies have significantly improved DLBCL outcomes, however challenges remain, including treatment toxicity, accessibility, and variability in patients' response. Future research should aim to optimize combination therapies, identify biomarkers predictive of response, and enhance toxicity management to improve patient care."

IO biomarker • Journal • Review • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • XPO1

Therapy Sequencing in Relapsed/Refractory MCL (ICML 2025) - P1, P1/2, P2, P3 | "Although a direct comparison between them has only been performed for ibrutinib and temsirolimus [23], covalent BTK inhibitor (cBTKi) single agent therapy has been consolidated as the standard of care after first-line CIT. Moreover, to address cBTKi failure, two anti-CD19 CAR-T cell therapy products, brexucabtagene autoleucel [20, 21] and lisocabtagene maraleucel [22], and the first noncovalent BTKi, pirtobrutinib [19], have recently been approved...Liso-cel only FDA approved; CIT, chemoimmunotherapy options include BR, R-BAC, R-CHOP, R-DHAP or R-DHAOx, R-GEMOx, paliative options (avoid bendamustine pre-CART apheresis); pirtobrutinib, available after cBTKi failure in second-line (EMA) but third-line (FDA); RM, rituximab maintenance...Orelabrutinib [18] is licensed only in China...Of note, both acalabrutinib and zanubrutinib induce lower rates of atrial fibrillation, hypertension, and bleeding compared to ibrutinib in randomized studies..."

IO biomarker • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Oncology • PLCG2 • TP53

Non-Hodgkin Lymphoma Mortality Trends and Disparities (2000-2023): A SEER Database Analysis (SOHO 2025) - "In recent years, the treatment landscape has evolved with the introduction of targeted therapies such as CAR T-cell therapy, antibody-drug conjugates (eg, polatuzumab vedotin), BTK inhibitors (eg, zanubrutinib), and bispecific antibodies (eg, glofitamab, epcoritamab). NHL mortality rates have steadily declined over the past two decades, with an accelerated decrease from 2020 to 2023. These improvements likely reflect the impact of novel therapies and earlier detection. Nonetheless, disparities in mortality persist across sex and racial/ethnic groups, underscoring the need for targeted public health strategies and equitable access to advanced treatments."

Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Advances in the Management of Relapsed/Refractory CLL and Richter Transformation (ICML 2025) - P=N/A, P2, P3 | "BRUIN CLL-321 is a phase 3, registrational study that evaluated pirtobrutinib compared to the investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) [23]...Nemtabrutinib is now being evaluated in the registrational, phase 3 BELLWAVE-010 trial (NCT05947851) for patients with R/R CLL, comparing nemtabrutinib plus venetoclax to venetoclax plus rituximab...An ongoing, open-label, first-in-human phase 1/2 study is evaluating the BTK degrader BGB-16673 as monotherapy in patients with R/R CLL [27, 28]...NX-2127 is an investigational, first-in-class BTK degrader currently being evaluated in a phase 1 trial for patients with relapsed or refractory B-cell malignancies, CLL [29, 30]...NX-5948 is another investigational and more selective BTK degrader in an ongoing Phase 1a/1b clinical trial...This trial aims to establish lisaftoclax plus acalabrutinib as a potential alternative to venetoclax-based BTKi combination..."

IO biomarker • Acute Myelogenous Leukemia • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • Small Lymphocytic Lymphoma • BCL2L1 • TP53

The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy. (PubMed, Blood Cell Ther) - "This case highlights the potential of epcoritamab combined with debulking therapy for treating CAR-T-refractory CD19-negative DLBCL. This is the first validated case in Japan showing that epcoritamab is a viable and safe treatment option for post-CAR-T relapse, addressing a critical unmet need in the current therapeutic landscape."

IO biomarker • Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gene Therapies • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD5 • CD79B • MYD88

Diagnosis and Management of Waldenstrom's Macroglobulinemia (ICML 2025) - P2 | "New or emerging options for patients progressing on c-BTKi include pirtobrutinib, BGB-16673, venetoclax, and sonrotoclax...CXCR4 antagonists such as plerixafor or ulocuplumab can sensitize CXCR4Mut-expressing WM cells to ibrutinib [22-24]...6 BTK Mutations BTKCys481 is the binding site for covalent BTK inhibitors (cBTK-i), including ibrutinib, zanubrutinib, acalabrutinib, orelabrutinib and tirabrutinib...For symptomatic treatment-naïve patients, chemoimmunotherapy with bendamustine and rituximab (Benda-R), dexamethasone, rituximab, and cyclophosphamide (DRC), as well as cBTK-i can be considered...Additional options in second or later relapse include re-use of chemotherapy if a response lasted for > 3 years, alternative chemoimmunotherapy, nucleoside analogs, or everolimus [38]...Zanubrutinib in combination with ixazomib and dexamethasone (ZID) is being investigated in a study in China (NCT04463953) and has shown high levels of response activity and good..."

IO biomarker • Hematological Malignancies • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia • BCLAF1 • CXCL12 • FOXO3 • IL10 • IL6 • IRAK4 • MYD88 • PLCG2 • SYK • TNFAIP3 • TRAF3IP2

New Immunotherapeutic Horizons in Richter's Transformation: Synergistic Approaches with Targeted Agents (SOHO 2025) - "BTK inhibitors, such as ibrutinib and zanubrutinib, have been shown to modulate immune function, reducing regulatory T-cell activity and altering cytokine profiles...Pembrolizumab and nivolumab achieved response rates of approximately 13% to 20%, with a median OS of less than 6 months...The landscape shifted with the RT1 trial, which evaluated the combination of tislelizumab, a PD-1 inhibitor, with zanubrutinib in 48 patients with RT...The MOLTO trial adopted a triplet strategy, combining atezolizumab, a PD-L1 inhibitor, with venetoclax and obinutuzumab...Support for combination strategies comes from a recent case series by Smith et al, in which six RT patients were treated with lisocabtagene maraleucel (liso-cel)...9,10 Given these encouraging results, epcoritamab is being tested in combination with venetoclax, R-CHOP, and other immune modulators...Other bispecific constructs under investigation include glofitamab and mosunetuzumab, each with distinct pharmacokinetic..."

IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • HAVCR2 • LAG3 • NOTCH1 • PD-L2 • TP53

Relapsed/Refractory Indolent Lymphoma: Options Beyond Immunotherapy (SOHO 2025) - "Third-line immunotherapy-based strategies are now approved for the treatment of patients with multiple relapses, including the chimeric antigen receptor T-cell (CAR-T) constructs axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, as well as bispecific antibodies like the anti-CD20 × CD3 agents mosunetuzumab and epcoritamab...Obinutuzumab was chosen as the companion of zanubrutinib due to the high proportion of rituximab-refractory patients enrolled in the study and was administered in both arms up to 20 infusions...Loncastuximab with Rituximab In a population of 39 advanced-stage FL patients, including 20 cases of disease relapse within 24 months since frontline treatment (POD24), the combination of the two drugs in an outpatient fixed-duration regimen produced a complete response rate of 67% after 12 weeks on-therapy, which rose to 77% within 21 weeks...Compared with existing agents targeting Ikaros/Aiolos, such as lenalidomide, avadomide, and..."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CRBN • IKZF1

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL (clinicaltrials.gov) - P2 | N=22 | Not yet recruiting | Sponsor: Zulfa Omer

New P2 trial • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

Follicular Lymphoma: Does The Choice of Frontline Treatment Matter? (SOHO 2025) - P1/2, P2 | "The most common frontline treatment approaches include bendamustine plus rituximab (BR), an anti-CD20 antibody plus chemotherapy — commonly R-CHOP, G-CHOP, or R-CVP — rituximab monotherapy, and a combination of an anti-CD20 antibody with lenalidomide...13, 14 This is also of growing concern for bispecific antibodies such as mosunutuzmab and epcoritamab — CD20 × CD3 bispecifics — that also engage T cells and have shown efficacy in the relapsed setting...Golcadomide is a novel oral cereblon E3 ligase modulatory drugs (CELMoD) that has been shown to have 10 – 100-fold enhanced antiproliferative and apoptotic activity compared to existing immunomodulatory agents such as lenalidomide. 24 This study will be instrumental in evaluating the role of obinutuzumab combined with cell-modulating agents in the frontline setting and could suggest avenues to shorten the duration of therapy."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Oncology • CRBN

First Disclosure of Epcoritamab+R-ICE in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Eligible For Autologous Stem Cell Transplantation (ASCT): EPCORE NHL-2 (SOHO 2025) - P1/2 | "Aim: We present results from the NHL-2 trial (NCT04663347) of epcoritamab, a subcutaneous CD3 × CD20 bispecific antibody, plus rituximab, ifosfamide, carboplatin, etoposide (R-ICE) in patients with R/R DLBCL eligible for ASCT. Epcoritamab +R-ICE demonstrated high CR rates in patients with R/R DLBCL eligible for ASCT. Safety was manageable. These results demonstrate that epcoritamab, when combined with CIT, may optimize salvage therapy, increasing the proportion of patients proceeding to ASCT compared with historical rates, providing a greater chance of a cure."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

The Optimal Management of Waldenström Macroglobulinemia (SOHO 2025) - "Standard treatment options include alkylating agents (eg, bend-amustine or cyclophosphamide) or proteasome inhibitors (eg, bortezomib, carfilzomib, or ixazomib) in combination with anti-CD20 monoclonal antibody rituximab, covalent Bruton tyrosine kinase (BKT) inhibitors (eg ibrutinib, acalabrutinib, or zanubrutinib), BCL2 antagonists (eg, venetoclax), and non-covalent BTK inhibitors (eg, pirtobrutinib) 13–23...The combination of bendamustine and rituximab showed superior progression-free survival (PFS) to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in a study by the STiL group 13...The all-oral, non-chemo, fixed-duration combination of pirtobrutinib and venetoclax has shown promise in early relapse 29.Inlate relapse, multiple agents are under active development, including second-generation BCL2 antagonists (eg, sonrotoclax), BTK degraders (eg, BGB-16673 30, NX-5948), conjugated radioisotopes (eg, iopofosine I-131 31), antibody-drug conjugates..."

IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Waldenstrom Macroglobulinemia • B2M • BCL2 • CXCR4 • MYD88 • TP53

Genmab Announces Financial Results for the First Half of 2025 (GlobeNewswire) - "Revenue was $1,640 million for the first six months of 2025 compared to $1,382 million for the first six months of 2024. The increase of $258 million, or 19%, was primarily driven by higher DARZALEX and Kesimpta royalties achieved under our collaborations with Johnson & Johnson (J&J) and Novartis Pharma AG (Novartis), respectively, and higher EPKINLY net product sales. Royalty revenue was $1,378 million in the first six months of 2025 compared to $1,111 million in the first six months of 2024, an increase of $267 million, or 24%. The increase in royalties was driven by higher net sales of DARZALEX and Kesimpta."

Commercial • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Multiple Myeloma • Multiple Sclerosis

Matching-Adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide Versus Tafasitamab With Rituximab + Lenalidomide in Second-Line or Later Follicular Lymphoma (SOHO 2025) - P1/2, P3 | "Findings from this MAIC highlight the potential of epcoritamab+R2 to deliver improved ORR, CR, and PFS versus tafasitamab+R2 in 2L+ FL. This abstract will be presented at EHA 2025; June 12-15, 2025; Milan, Italy."

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

New Targets and Drugs on the Horizon in Chronic Lymphocytic Leukemia (SOHO 2025) - P1, P1/2 | "12 Treatment planning for patients with " double refractory " CLL — CLL that is resistant to a covalent BTKi and venetoclax — is a relatively novel but emerging scenario in the clinic...Noncovalent (Reversible) BTK Inhibitors In the BRUIN-321 phase 3 randomized trial of pirtobrutinib monotherapy versus the control arm of the investigator's choice between idealisib plus rituximab or bendamustine plus rituximab, pirtobrutinib had improved PFS (14 vs 8.7 months, Hazard ratio [HR] 0.54, P = 0.0002) and a superior time to next treatment or death compared to the control arm (24 vs 10.9 months, HR 0.37, P < 0.0001)...Nemtabrutinib is another noncovalent BTKi under clinical investigation, demonstrating an overall response rate (ORR) of 36.4% in CLL patients in the phase 1 study (n = 22 patients)...23,24 Thus far, data for three orally administered BTK degraders — NX-2127, NX-5948 and BGB-16673 23–25— have been presented, and there are ongoing clinical..."

IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Leukemia • Lymphoma • Oncology • CD20 • PRKCB • PRKCH • ROR1

Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma. (PubMed, Blood) - P1/2 | "We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE® NHL-2 (phase 1b/2; NCT04663347). CRS events were mostly low grade (38% G1, 11% G2, 2% G3), all resolved, and none led to epcoritamab discontinuation. Fixed-duration epcoritamab plus R2 demonstrated deep, durable responses with manageable safety and favorable outcomes in R/R FL, irrespective of risk features."

Journal • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Novel Coronavirus Disease • Oncology

ECLAT: A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - P2 | N=27 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for B-Cell Lymphomas, Version 3.2025. (NCCN)

NCCN guideline • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • High-grade B-cell lymphoma • Mantle Cell Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

ALLG CLL10/CLLRT2: A prospective, open-label, randomised, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation (ANZCTR) - P3 | N=116 | Not yet recruiting | Sponsor: Australasian Leukaemia and Lymphoma Group

New P3 trial • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Richter's Syndrome

Bispecific Antibodies in R/R Lymphomas: Practice-Ready Evidence From Clinical Trials (SOHO 2025) - "Intervention: CD20 × CD3 BsAbs, combination therapies— including glofitamab plus gemcitabine-oxaliplatin (GemOx)— glofitamab monotherapy, and epcoritamab monotherapy...Glofitamab plus GemOx significantly improved OS (25.5 vs 12.9 months; hazard ratio [HR], 0.62) and PFS (13.8 vs 3.6 months; HR, 0.40) versus rituximab plus GemOx, with higher CR rates (50.3% vs 22.0%)... BsAbs show clinically meaningful activity in R/R lymphomas, with distinct efficacy profiles by histology. Glofitamab-based regimens demonstrate survival benefits in DLBCL, while epcoritamab excels in FL. Safety is manageable with protocolized approaches."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Patients With Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis (SOHO 2025) - P1/2, P3 | "Epcoritamab+GemOx showed significantly superior ORR versus R-GemOx and a trend toward higher CR rates versus Glofi+GemOx. Findings support Epcoritamab+GemOx as an alternative therapy in transplant-ineligible patients with R/R DLBCL. This abstract was previously published at the American Society of Hematology Annual Meeting and Exposition, December 7-10, 2024, San Diego, CA, USA."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology